Development of CDK4/6 Inhibitors: A Five Years Update
Alessandra Ammazzalorso1, Mariangela Agamennone1, Barbara De Filippis1
1Unit of Medicinal Chemistry, Department of Pharmacy, "G. d'Annunzio" University, 66100 Chieti, Italy.
Molecules (Basel, Switzerland)
|April 3, 2021
Summary
New CDK4/6 inhibitors show promise for treating advanced breast cancer resistant to aromatase inhibitors. Research focuses on improving selectivity and reducing side effects for better patient outcomes.
Area of Science:
- Oncology
- Pharmacology
- Medicinal Chemistry
Background:
- Metastatic breast cancer often develops resistance to aromatase inhibitors.
- Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulators of cell cycle progression.
- Approved CDK4/6 inhibitors combined with endocrine therapy have significantly improved survival in breast cancer.
Purpose of the Study:
- To review recent advancements in the development of novel selective CDK4/6 inhibitors.
- To explore small-molecule inhibitors and proteolysis-targeting chimeras (PROTACs) for enhanced cancer treatment.
- To analyze structure-activity relationships, kinase selectivity, and antiproliferative effects of new inhibitors.
Main Methods:
- Literature review of recent studies on CDK4/6 inhibitors.
- Analysis of structure-activity relationships for small-molecule inhibitors.
- Evaluation of PROTACs as an emerging therapeutic strategy.
- Assessment of kinase selectivity and antiproliferative activity data.
Main Results:
- Several new selective CDK4/6 inhibitors demonstrate improved efficacy and safety profiles.
- PROTACs targeting CDK4/6 represent a promising novel approach.
- Structure-activity relationship studies guide the design of more potent and selective inhibitors.
Conclusions:
- Ongoing research aims to develop next-generation CDK4/6 inhibitors with superior clinical profiles.
- Targeting CDK4/6 remains a critical strategy for overcoming endocrine resistance in breast cancer.
- Future developments may include combination therapies and novel drug delivery systems.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.2K
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
10.5K
Related Concept Videos
02:34Inhibition of Cdk Activity
5.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
02:15M-Cdk Drives Transition Into Mitosis
5.9K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.9K
02:39Positive Regulator Molecules
6.1K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.1K
01:11Clinical Trials: Overview
4.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.1K
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
01:28Preclinical Development: Overview
5.4K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.4K